Arbutus Biopharma Corp Files 8-K Report

Ticker: ABUS · Form: 8-K · Filed: 2025-03-03T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, corporate-filing

TL;DR

Arbutus Biopharma filed an 8-K on March 3, 2025, reporting a material definitive agreement and other events.

AI Summary

On March 3, 2025, Arbutus Biopharma Corporation filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

Why It Matters

This filing indicates significant corporate activity and potential changes for Arbutus Biopharma, requiring investor attention to understand the implications of the material definitive agreement and other reported events.

Risk Assessment

Risk Level: medium — The filing of an 8-K, especially one involving a material definitive agreement, can signal significant corporate developments that may impact the company's stock price and future prospects.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement reported by Arbutus Biopharma Corporation?

The filing does not specify the details of the material definitive agreement, only that one has been entered into.

When was the 8-K report filed by Arbutus Biopharma Corporation?

The 8-K report was filed on March 3, 2025.

What was Arbutus Biopharma Corporation's former name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

What is the principal executive office address for Arbutus Biopharma Corporation?

The principal executive office is located at 701 Veterans Circle, Warminster, Pennsylvania 18974.

Under which section of the Securities Exchange Act is this 8-K report filed?

This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0001171843-25-001188.txt : 20250303 0001171843-25-001188.hdr.sgml : 20250303 20250303092459 ACCESSION NUMBER: 0001171843-25-001188 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250303 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250303 DATE AS OF CHANGE: 20250303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 25694519 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_030325.htm FORM 8-K Form 8-K 0001447028 False 0001447028 2025-03-03 2025-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  March 3, 2025 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 1.01. Entry into a Material Definitive Agreement. On March 2, 2025, Arbutus Biopharma Corporation (the “Company”) and Genevant Sciences GmbH, as assignee of Genevant Sciences Ltd. (“Genevant”), entered into an agreement (the “Agreement”) related to that certain Cross License Agreement, dated as of April 11, 2018, by and between the Company and Genevant, as amended. Pursuant to the Agreement, the Company and Genevant memorial

View on Read The Filing